Dr Lalchandani Labs Limited has completed the dispatch of rights issue material for its upcoming equity offering, as announced in a regulatory filing dated January 31, 2026. The company has notified BSE Limited about the newspaper publication intimation under relevant SEBI regulations regarding the completion of rights issue dispatch.

Rights Issue Details

The company is offering up to 43,32,000 fully paid-up equity shares of face value ₹10 each for cash at par, at a price of ₹10 per rights equity share. The total issue size aggregates up to ₹433.20 lakhs, assuming full subscription.

Issue Timeline

The rights issue follows a structured timeline for eligible equity shareholders to participate in the offering.

Application Process and Requirements

All shareholders desiring to make an application in this issue are mandatorily required to use the Application Supported by Blocked Amount (ASBA) process in accordance with SEBI regulations. The credit of rights entitlements and allotment of rights equity shares shall be made in dematerialised form only.

The company has established a separate demat suspense escrow account named "DR LALCHANDANI LABS LIMITED RIGHTS ISSUE SUSPENSE ESCROW DEMAT ACCOUNT" for specific cases where rights entitlements cannot be directly credited to eligible shareholders' accounts.

Eligible Shareholders and Restrictions

The rights issue is available to eligible equity shareholders as on the record date of January 27, 2026. The company has dispatched issue material through email to shareholders who provided valid email addresses, while physical dispatch has been completed for those without email addresses on a reasonable effort basis.

Eligible equity shareholders who do not receive application forms may apply on plain paper under the ASBA process, provided they include all required details as specified in the regulations. However, shareholders making applications on plain paper will not be entitled to renounce their rights entitlements.

Regulatory Compliance

The announcement was made in compliance with Regulation 84(1) of SEBI ICDR Regulations and Regulation 30 of SEBI LODR Regulations. The newspaper advertisements were published in Financial Express (English - All Edition) and Jansatta (Hindi - All editions) on January 31, 2026, providing details about the completion of dispatch and information for obtaining duplicate application forms.

Dr Lalchandani Labs Limited's board of directors has approved the detailed terms for its proposed rights issue of equity shares during a meeting held on January 20, 2026. The comprehensive approval follows earlier intimations from December 2025 and establishes the framework for the company's capital raising initiative.

Rights Issue Structure and Pricing

The board approved the issuance of 43.32 lakh fully paid-up equity shares with a face value of ₹10.00 each. The rights issue is priced at ₹10.00 per share, matching the face value, with the entire issue price payable at the time of application.

Timeline and Key Dates

The company has established a comprehensive schedule for the rights issue process. The record date for determining eligible shareholders is set for January 27, 2026, with the issue opening on February 4, 2026.

The board retains the right to extend the issue period, though it cannot remain open for more than 30 days from the opening date. No withdrawal of applications will be permitted after the issue closing date.

Share Capital Impact

The rights issue will significantly impact the company's equity structure. Currently, Dr Lalchandani Labs has 43.33 lakh outstanding fully paid-up equity shares of ₹10.00 face value each.

Assuming full subscription and payment, the total outstanding equity shares will reach 86.65 lakh shares, effectively doubling the company's equity base.

Regulatory Compliance and Process

The company has initiated the process for obtaining an International Securities Identification Number (ISIN) for the rights entitlements from depositories. This ISIN will be disclosed in the Letter of Offer once received. In compliance with SEBI Master Circular dated November 11, 2024, Dr Lalchandani Labs has arranged with NSDL and CDSL for crediting Rights Entitlements in dematerialized form to eligible shareholders' demat accounts. The Rights Entitlements will be credited before the issue opening date under the designated ISIN.

The board meeting commenced at 5:00 PM and concluded at 5:50 PM on January 20, 2026, with Managing Director Arjan Lalchandani (DIN: 07014579) signing the regulatory filing.